Reported Earnings • May 08
First quarter 2026 earnings released: US$0.88 loss per share (vs US$2.04 profit in 1Q 2025) First quarter 2026 results: US$0.88 loss per share (down from US$2.04 profit in 1Q 2025). Revenue: US$1.27b (up 92% from 1Q 2025). Net loss: US$72.0m (down 159% from profit in 1Q 2025). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. 공시 • May 06
Waters Corporation Provides Earnings Guidance for the Second Quarter Ending July 4, 2026 and Full Year Ending December 31, 2026 Waters Corporation provided earnings guidance for the second quarter ending July 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue for the second quarter of 2026 is expected to be in the range of $1.616 billion to $1.631 billion.
For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis. 공시 • Apr 15
Waters Corporation Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC Powering Rapid Characterization of Large Molecules Waters Corporation announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio. Featuring 18 angles of detection, the omniDAWN Photometer is the first extended-range MALS detector for Ultra High Performance Liquid Chromatography (UHPLC) and Ultra Performance Liquid Chromatography (UPLC) workflows, delivering absolute molar mass and size measurements without compromising resolution or throughput. The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, from approximately 50 to 500 nm in radius, enabling reliable characterization of larger, more complex analytes such as protein aggregates, viral vectors, lipid nanoparticles (LNPs), and advanced materials. Because it provides absolute molar mass and size, the omniDAWN Photometer reduces reliance on column calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. Integrating seamlessly with Waters UPLC Systems and columns, the omniDAWN Photometer eliminates traditional trade-offs between dispersion, robustness, and analytical performance, delivering a complete solution for multi-attribute characterization with improved usability compared to micro-volume MALS approaches. When paired with UHPLC or UPLC Systems, the omniDAWN Photometer supports run times up to four times faster than conventional HPLC workflows, while reducing sample consumption by 30–50% and solvent use by approximately 40%. Its low dispersion design preserves resolution and sensitivity, while delivering high-quality data across complex samples. Sharper separations enhance the detection of low-level species, helping scientists distinguish monomer, aggregates, and fragments with greater clarity, supporting informed decision-making across discovery, development, and quality workflows. The omniDAWN Photometer is powered by ASTRA Software, built on more than 40 years of light scattering innovation. By integrating MALS with ultraviolet (UV) and refractive index (RI) detection, ASTRA Software enables comprehensive analysis of size, composition, and heterogeneity in a single run, with dedicated workflows for ADCs, LNPs, and viral vectors. The platform is 21 CFR Part 11 and EU Annex 11 compliant and will be compatible with Waters Empower Software later this year. The Waters omniDAWN MALS Photometer will be available globally in summer 2026. 공시 • Apr 10
Waters Corporation, Annual General Meeting, May 21, 2026 Waters Corporation, Annual General Meeting, May 21, 2026. 공시 • Apr 08
Waters Corporation Announces U.S. Food and Drug Administration Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay Waters Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening. Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the virus responsible for nearly all cervical cancers. Approximately 60% of cervical cancer cases occur in individuals who are unscreened or under-screened. Expanding screening options and access, including at-home self-collection, has been identified by public health experts as an instrumental strategy for improving early detection and reducing cervical cancer deaths. The kit is tested with the BD Onclarity HPV Assay, which detects all of the high-risk, carcinogenic genotypes of HPV and is the only FDA-approved HPV assay to identify six individually and three groups of pooled results, making it the most comprehensive HPV screening tool available in the U.S. today. Samples are processed on the fully automated BD COR System, which uses advanced robotics to prepare, analyze, and report results while preserving specimen integrity and ensuring reliable, high-quality outcomes. Waters collaborated with the National Institutes of Health's (NIH) National Cancer Institute (NCI) through the Cervical Cancer 'Last Mile' Initiative SHIP Trial to evaluate the accuracy of self-collection for HPV testing. Waters is currently establishing partnerships to enable broader nationwide access to the Onclarity HPV Self-Collection Kit, which is expected to be available by prescription in the coming months. Covered by private insurance, Medicaid, and Medicare, the kit can be mailed directly to a patient's home, allowing them to collect a sample at their convenience and mail it to a laboratory for processing. Results are shared with the patient's healthcare provider to guide follow-up and care decisions. The Onclarity HPV Self-Collection Kit, Onclarity HPV Assay, and BD COR System are manufactured by Becton, Dickinson and Company or one of its affiliates or subsidiaries. 공시 • Mar 10
Waters Corporation Launches ARES-G3 Rheometer Waters Corporation launched the ARES-G3 Rheometer, part of the TA Instruments product line. This next-generation rheometer delivers industry-leading speed paired with best-in-class data to accelerate materials research and product development. Capturing up to 25,000 data points per second (10x more than its predecessor) and cutting standard test times by up to 80% through fully integrated Fast Frequency Chirps, the ARES-G3 Rheometer addresses pressing industry limitations. The ARES-G3 Rheometer enables shortened experiment times, increased lab throughput, and previously unobtainable measurements of fast-changing samples in a single test. Because it fully integrates a Fast Frequency Chirps solution into its enhanced TRIOS Software, the ARES-G3 Rheometer eliminates the need for multiple software licenses and training in advanced programming packages to capture and process data through rapid frequency sweeps. Routine quality control tests and data generation can also be completed up to 80% faster than before with some tests reduced from six hours to one; this translates to accelerated workflows that save teams hundreds of workdays per year under typical conditions, without sacrificing data quality. The ARES-G3 Rheometer can also perform many tests without requiring user calibrations, reducing margin for human error and increasing confidence in measurements. The ARES-G3 Rheometer builds on the flagship legacy of its predecessor, improving at-instrument control with a new touchscreen, enhancing data capture with hardware and software updates, and preserving its core proprietary, fully integrated dynamic mechanical analysis (DMA) capabilities and purpose-built hardware for both stress measurement and strain control. Retaining the best-in-class oven of the ARES-G2 Rheometer, this next-generation rheometer delivers low-oxygen atmosphere control and temperature uniformity, further simplifying the process of simulating real-world processing conditions, and enabling scientists to explore new rheological methods and gain a deeper understanding of structure-property relationships. All existing ARES-G2 Rheometer methods and fixtures remain fully compatible with the ARES-G3 Rheometer. The Waters TA Instruments ARES-G3 Rheometer is available for order. 
